Big obesity bets and China's rise fuel potential $2T in 2032 drug sales: Evaluate
22nd June 2026 Uncategorised 0While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as pipelines bring massive sales opportunities to bear.
More: Big obesity bets and China's rise fuel potential T in 2032 drug sales: Evaluate
Source: fierce